| 发明名称 | Therapeutic and diagnostic target | ||
| 摘要 | The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases. | ||
| 申请公布号 | US9447178(B2) | 申请公布日期 | 2016.09.20 |
| 申请号 | US201214127788 | 申请日期 | 2012.06.28 |
| 申请人 | Oxford BioTherapeutics Ltd. | 发明人 | Rohlff Christian;Stamps Alasdair |
| 分类号 | A61K39/395;C07K16/18;A61K39/00;C07K16/00;C07K16/28;C07K16/30;C12Q1/68;G01N33/574;C07K14/435;G01N33/566 | 主分类号 | A61K39/395 |
| 代理机构 | Nelson Mullins Riley & Scarborough LLP | 代理人 | Nelson Mullins Riley & Scarborough LLP ;Remillard, Esq. Jane E.;Sloper, Esq. Jill Gorny |
| 主权项 | 1. A method for the treatment of disease wherein BST1 is expressed in said disease, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody, or a functional fragment thereof, which binds to BST1, wherein said disease is acute myeloid leukemia (AML). | ||
| 地址 | Abingdon GB | ||